Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension

P Peter Nordbeck O Ozlem Goker-Alpan J John A. Bernat D Dominique P. Germain P Pilar Giraldo A Ana Jovanović V Virginia Kimonis K Kathleen Nicholls C Cheryl Rockman-Greenberg R Raphael Schiffmann M Mark Thomas A Anna Tylki-Szymanska E Eric Wallace R Richard W. D. Welford M Michael L. West M Martine Clozel A Aline Frey L Luba Trokan M Markus S. Mueller M Markus Vogler C Christoph Wanner D Derralynn Hughes

Article Details

Volume / Issue Vol. 17, Issue 1
Published January 10, 2026
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (22)

P

Peter Nordbeck

O

Ozlem Goker-Alpan

J

John A. Bernat

D

Dominique P. Germain

P

Pilar Giraldo

A

Ana Jovanović

V

Virginia Kimonis

K

Kathleen Nicholls

C

Cheryl Rockman-Greenberg

R

Raphael Schiffmann

M

Mark Thomas

A

Anna Tylki-Szymanska

E

Eric Wallace

R

Richard W. D. Welford

M

Michael L. West

M

Martine Clozel

A

Aline Frey

L

Luba Trokan

M

Markus S. Mueller

M

Markus Vogler

C

Christoph Wanner

D

Derralynn Hughes